SII Receives First Indian License for Hib Vaccine

Article

Serum Institute of India Ltd. (SII Ltd., Pune, India, www.seruminstitute.com) has developed a vaccine against Hib (Haemophilus influenza type b) and obtained a license from the Indian Government for its production.

Serum Institute of India Ltd. (SII Ltd., Pune, India, www.seruminstitute.com) has developed a vaccine against Hib (Haemophilus influenza type b) and obtained a license from the Indian Government for its production. The pilot process technology know-how came from the Netherlands Vaccine Institute (NVI, Bilthoven, the Netherlands, www.nvi-vaccin.nl). This is the first time that through intensive joint development and technology transfer a developing country vaccine manufacturer has developed a Hib vaccine successfully and obtained a license for it.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Daniel Fischer, Tevard
Related Content
© 2025 MJH Life Sciences

All rights reserved.